American Bio Medica Generates Record November Sales.

HUDSON, N.Y.--(BW HealthWire)--Dec. 2, 1998--American Bio Medica Corporation (NASDAQ:ABMC) today announced that it had record sales of $628,000 in November, representing 48% of total first quarter fiscal 1999 sales.

The Company said that greater sales of its Rapid Drug Screen(tm) family of products to the corrections and clinical market segments in the U.S. were the primary contributing factors to the November increase.

ABMC President and CEO Stan Cipkowski remarked, "Our primary goal is to continue achieving consistent revenue growth by significantly advancing our presence in the industry's most dynamic segments. As we capture increased market share not only in the corrections and clinical areas, but also in the workplace, educational, and other high-growth sectors, we expect to further expand sales levels."

American Bio Medica Corporation develops, manufactures, and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits and support services worldwide. The Company's global distributors target the workplace, clinical, rehabilitation, physicians, corrections, and educational markets. ABMC's Rapid Drug Screen is proven to correlate 100% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.